An injectable monoclonal antibody that targets the insulin-like growth factor I receptor improved proptosis in more than half of people with chronic thyroid eye disease, according to topline results from the REVEAL-2 trial.
As Healio previously reported, elegrobart (Viridian Therapeutics) was associated with a higher percentage of adults with active thyroid eye disease having an improvement in proptosis at 24 weeks compared with placebo in the REVEAL-1 trial. The REVEAL-2 trial assessed the investigational therapy among patients with chronic thyroid eye disease. The trial included 204 adults